Casdin Capital, LLC Allogene Therapeutics, Inc. Transaction History

Casdin Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $20.3 Million - $40.5 Million	-2,650,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $7.22 Million - $13.5 Million	550,000 Added 26.19%	2,650,000 $39.5 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $18.4 Million - $24.2 Million	875,000 Added 71.43%	2,100,000 $54 Million
Q2 2021 Aug 16, 2021	SELL	$23.49 - $35.8 $1.76 Million - $2.69 Million	-75,000 Reduced 5.77%	1,225,000 $31.9 Million
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $9.16 Million - $13.9 Million	355,000 Added 37.57%	1,300,000 $45.9 Million
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $10.4 Million - $14.4 Million	320,000 Added 51.2%	945,000 $35.6 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $2.3 Million - $6.76 Million	125,000 Added 25.0%	625,000 $26.8 Million
Q1 2020 May 15, 2020	BUY	$18.22 - $28.25 $9.11 Million - $14.1 Million	500,000 New	500,000 $9.72 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $265M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Casdin Capital, LLC with notifications on news.